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Summary 
No data are available about the possible role of endothelial pro-
genitor cells (EPCs), cytochemokines and N-terminal pro-brain 
natriuretic peptide (NT-proBNP) in determining a different re-
sponse to short period of cardiologic rehabilitation (CR), as 
measured by the improvement of exercise capacity. In a popu-
lation of 86 cardiac surgery patients, we evaluated the numbers 
of EPCs, pro- and anti-inflammatory cytokines (IL-6,IL-8, IL-10, 
IL-1ra), hs-C-reactive protein (CRP), vascular endothelial 
growth factor (VEGF) and NT-proBNP before (T1), and after 15 
days of CR (T2). EPCs were measured by flow cytometry, and 
the exercise capacity was measured at T1 and T2 by using the six-
minute walk test (6MWT). At T2, a significant increase of 6MWT 
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(p<0.0001) was detected. No significant increase of EPCs was 
observed, while a significant (at least p<0.05) decrease in cy-
tochemokines, CRP and NT-ProBNP levels was evidenced. By 
analyzing the median improvement of 6MWT, only patients with 
a median improvement ≥23% showed a significant (p<0.05) in-
crease of EPCs at T2, with significant correlations between 
EPCs, VEGF and IL-10. On the contrary, in patients with a medi-
an improvement <23% a negative correlation between CRP and 
EPCs was observed. Finally, CD34+/KDR+ EPCs showed signifi-
cant correlation with IL-8 at T1. In conclusion, a short period of 
CR intervention determines a different pattern of modifications 
for EPCs in relation to the improvement of exercise capacity.  
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Introduction 
During the last years, increasing evidence showing that vascular 
function depends not only on cells that reside within the vessel 
but also on circulating cells derived from bone marrow, has been 
reported (1). Indeed, a specific subset of these stem cells, named 
endothelial progenitor cells (EPCs), has been shown to enhance 
angiogenesis, promote vascular repair and improve endothelial 
function (2–3).  
Physical exercise has recently been demonstrated to be ca-
pable to mobilise EPCs from the bone marrow (4–7). However, 
this phenomenon may be transient and the specific grade of ex-
ercise required to mobilise EPCs has not been yet determined.  
Upregulation of EPCs by exercise is dependent, at least in 
part, from the increased activity of endothelial nitric oxide syn-
thase and from the subsequently increase in nitric oxide (NO) 
bioavailability (8–9); however, despite recent advances in EPCs’ 
research, the mechanisms stimulating the increase of circulating 
EPCs’ numbers are not completely known. At present, a various 
number of cytokines and chemokines, such as vascular endothe-
lial growth factor (VEGF), granulocyte colony stimulating fac-
tor (G-CSF) and interleukin-8 (IL-8), able to enhance the mobi-
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lization of EPCs, can be involved in exercise-induced release of 
EPCs from the bone-marrow (10–12). 
Actually, EPCs have been analysed in different clinical set-
tings in relation to physical training and exercise and recently, in 
a report by Paul et al. (13), an increase of circulating EPCs in 46 
patients after a cardiac rehabilitation program lasting for three 
months has been reported. To the best of our knowledge, no data 
are available on the effect of a shorter period of cardiac rehabili-
tation intervention, and on the improvement of exercise capacity 
in relation to EPCs’ number.  
Thus, we aimed at evaluating, in patients who underwent car-
diac surgery, the possible role of EPCs, cytochemokines and NT-
proBNP in determining a different response to short period of 
cardiologic rehabilitation (CR), as measured by the improve-
ment of exercise capacity. 
Materials and methods  
Study population 
The study population comprised 86 patients admitted to the 
Units of Cardiac Rehabilitation “Ulivella and Glicini” and “Don 
Carlo Gnocchi Foundation” of Florence, Italy, included in a co-
hort of patients previously investigated (14). All patients under-
went a cardiac surgery at the Department of Heart and Vessels of 
the University of Florence, Italy. 
Thirty-seven (28 male; 9 female) patients with a median age 
of 73 (58–84) years underwent coronary artery bypass grafting, 
and 49 (23 male; 26 female) patients with a median age of 72 
(47–88) years underwent a valve replacement. 
The subjects were classified as having hypertension accord-
ing to the guidelines of European Society of Hypertension/Euro-
pean Society of Cardiology (15) or if they reported taking antihy-
pertensive medications, as verified by the physician. Diabetic 
subjects were defined in agreement with the American Diabetes 
Association (16) or on the basis of self-report data (if confirmed 
by medication or chart review). Dyslipidemia was defined ac-
cording to the Third report of the National Cholesterol Education 
Program (NCEP-III) or if they reported taking antidyslipidemic 
drugs, as verified by the physician (17). A positive family history 
was defined as the presence of at least one first-degree relative 
who had developed coronary artery disease before the age of 55 
years for men and 65 years for women. 
All subjects gave informed consent; the study complies with 
the Declaration of Helsinki and was approved by the local ethic 
committee.  
Cardiac rehabilitation (CR) 
All patients were included in the CR protocol that lasted for 15 
days. The rehabilitation program began between 10–15 days 
after the cardiac surgery, and comprised optimal medication ad-
justment according to the available guidelines (18), physical 
training prescription based on the result of the six-minute walk 
test (6MWT) and serial clinical and instrumental examinations. 
In detail, physical training included aerobic exercise at cycle er-
gometer, based on the maximal heart rate recorded during the 
6MWT performed on admission; gentle, low-level (25 W), and 
short lasting (1–2 minutes [min]) calisthenic exercises, with the 
resistance sequentially provided by the weight of single body 
segments and gentle, passive stretching involving all the main 
joints. The training frequency was six times per week for a total 
of 12 training sessions.  
6MWT 
All subjects performed the 6MWT at the onset and at the end of 
the cardiac rehabilitation intervention according to the American 
Thoracic Society (19) protocol with electrocardiographic moni-
toring by telemetry. 
Blood collection 
Blood samples were obtained in the morning after an overnight 
fasting at two time points for each patient: at the onset of the re-
habilitation program and at the end of the rehabilitation program 
at least 48 hours after the last program of exercise in the cardiac 
rehabilitation protocols. Blood samples were collected from the 
antecubital vein into evacuated plastic tubes (Vacutainer) con-
taining ethylenediaminotetracetate (EDTA) 0.17 M for obtain-
ing plasma samples and for EPCs’ evaluation and with no antico-
agulant for obtaining sera samples. The samples were centri-
fuged at 2,000 g for 10 min a 4°C and then stored in aliquots at 
–80°C until analysis. 
Flow cytometric analysis 
EPCs were evaluated by flow cytometry as previously described 
(14). Circulating EPCs were identified through their expression 
of CD34, KDR, and CD133 and were considered as EPCs cells 
CD34+/KDR+; CD133+/KDR+ and CD34/CD133+/KDR+. 
The intra- and inter-observer variations of our method 
showed an intraclass correlation coefficient of 0.97 and 0.92, re-
spectively (n=20 determinations). 
Cytochemokines’ analysis 
Quantitative determination of sera levels of IL-6, IL-8, IL-10, 
VEGF and IL-1 receptor antagonist (IL-1ra) were performed in 
duplicate by using the Bio-Plex cytokine assay (Bio-Rad Lab-
oratories Inc, Hercules, CA, USA) according to manufacturer’s 
instructions.  
High sensitivity C-reactive protein (hsCRP) 
determination 
CRP was assessed with a high-sensitivity assay on a BN II nep-
helometer (Dade Behring, Marburg, Germany). 
NT-pro-BNP determination 
NT-pro-BNP was measured with a chemiluminescent immu-
noassay kit (Roche Diagnostic Laboratory, Indianapolis, IN, 
USA) on an Elecsys 2010 analyser. 
Statistical analysis 
Statistical analysis was performed using the SPSS (Statistical 
Package for Social Sciences, Chicago, IL, USA) software for 
Windows (Version 13.0). Values are presented as median and 
range.  
The Mann-Whitney test for unpaired data was used for com-
parison between groups. The Wilcoxon test for related data was 
used to evaluate differences between two time-points. 
Cesari et al. Endothelial progenitor cells and exercise capacity
523
In order to analyse EPCs’ number in relation to the exercise 
capacity we calculated the delta (Δ) of the 6MWT improvement 
(end-onset of the rehabilitation) for each patient and we divided 
our study population according to the median percentage of im-
provement (23%).  
Post-hoc sample size calculation indicated that the number of 
43 patients for group has a sufficient statistical power 
(Beta=0.80) to detect a significant difference in EPC number be-
tween groups according to the improvement of exercise capacity, 
with an alpha coefficient of 0.05.  
Results 
Demographic and clinical characteristics of the study population 
are summarised in Table 1. 
The baseline median value of the 6MWT in the whole study 
population was 304 (53–560) m, with a significant difference ac-
cording to age: in fact, 6MWT was significantly reduced in older 
(≥72 years) than in younger patients (<72 years) [289 (53–380) 
vs. 320 (66–560) m; p<0.0001]. In addition, baseline 6WTC 
showed a significant negative correlation with baseline levels of 
NT-ProBNP (r=- 0.31 p=0.006), whereas no relationships were 
observed between 6MWT, cytochemokines and EPCs.  
Similar to 6MWT, circulating EPCs were also significantly 
(p<0.01) influenced by age; in fact, lower EPCs’ number was ob-
served in older (≥72 years) than in younger patients (<72 years) 
[CD34+/KDR: 0.21 (0–1.65) vs. 0.35 (0–1.34) cells/μl, p=0.02; 
CD133+/KDR+: 0.19 (0–0.75) vs. 0.30 (0–1.18) cells/μl, 
p=0.03; CD34+/CD133+/KDR+: 0.14 (0–1.58) vs. 0.22 
(0–1.13) cells/μl, p=0.03].  
No significant differences of EPCs in relation to other tradi-
tional cardiovascular risk factors or by medications were ob-
served.  
Patients with POAD showed lower number of EPCs than pa-
tients without [CD34+/KDR: 0.033 (0–1.65) vs. 0.28 (0–1.34) 
cells/μl, p=0.01; CD133+/KDR+: 0.082 (0.03–0.20) vs. 0.25 
(0–1.18) cells/μl, p=0.01, respectively].  
Among pro and anti-inflammatory cytochemokines, no sig-
nificant difference according to age, comorbidities or cardiovas-
cular risk factors was observed. Nonetheless, in relation to medi-
cations, IL-10, VEGF and IL-8 showed higher levels in patients 
under ACE-inhibitors treatment (p=0.02; p=0.009; and p<0.01; 
respectively). A significant (p=0.001) difference for circulating 
levels of NT-ProBNP according to age was found [NT-ProBNP: 
1970 (16–12240) vs 823.7 (331–4606) pg/ml, for patients older 
and younger than 72 years, respectively]. 
At baseline, a positive association between all the three types 
of EPCs and IL-10 and VEGF was observed [CD34+/KDR and 
IL-10: r=0.24, p<0.01; CD133+/KDR+ and IL-10: r=0.28, 
p=0.009; CD34+/CD133+/KDR+ and IL-10: r=0.28, p=0.009; 
CD34+/KDR and VEGF: r=0.21, p<0.05; CD133+/KDR+ and 
VEGF: r=0.22, p<0.01; CD34+/CD133+/KDR+ and VEGF: 
r=0.26, p<0.01]. Moreover, CD34+/KDR+ EPCs showed a sig-
nificant correlation with plasma levels of IL-8 (r=0.33, 
p=0.002). 
Modifications of 6MWT, EPC number, cytochemokines, 
hsCRP and NT-ProBNP after CR and in relation to 
exercise capacity 
A significant increase of 6MWT was detected at the end of the 
CR program [375 (54–580) m vs. 304 (53–560) m, p<0.0001], in 
both old and young patients. In older patients (≥72 years) the 
final 6MWT was significant lower than in younger patients (<72 
years) [345 (54–468) m vs. 400 (105–580) m; p<0.0001, respect-
ively] and a negative association between the 6MWT and NT-
ProBNP levels was detected (r=- 0.24, p=0.03). 
After 15 days of rehabilitation period, the number of circu-
lating EPCs were similar, while a significant decrease in cy-
tochemokines, hsCRP and NT-ProBNP levels was evidenced 
(Table 2).  
When data were analysed in relation to the improvement of 
exercise capacity, a significant difference of EPCs between pa-
tients with an improvement ≥ 23% in the 6MWT (median per-
centage of improvement among the whole study population) 
with respect to patients with a median improvement <23%, was 
demonstrated (Table 3). Furthermore, patients with a median im-
provement of 6MWT≥23% showed significantly lower levels of 
IL1ra with respect to patients with a median improvement <23% 
(Table 3). Moreover, by dividing patients according to the tertiles 
of improvement in the 6MWT [1st tertile: <20.43%, 2nd tertile: 
Variable 
Age (years) * 72.5 (47–88) 
Males, n (%) 51 (59.3) 
Cardiovascular risk factors 
Hypertension, n (%) 50 (58.1) 
Smoking habit, n (%) 39 (45.3) 
Dyslipidemia, n (%) 41 (47.7) 
Diabetes, n (%) 17 (19.8) 
Familial history of CVD, n (%) 33 (38.4) 
LVEF < 50%, n (%) 10 (11.6) 
Medications 
Statins, n (%) 24 (27.9) 
ACE inhibitors, n (%) 24 (27.9) 
Antiplatelet drugs, n (%)  33 (38.4) 
β-blockers, n (%) 23 (26.7) 
*Median and range. ACE, angiotensin converting enzyme; BMI, body mass index; COPD, chronic 
obstructive pulmonary disease; CVD,  cardiovascular diseases; LVEF, left ventricular ejection fraction; 
POAD, peripheral occlusive arterial disease; TIA, transient ischaemic attack. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BMI > 25 (kg/m2), n (%)  55 (63.9) 
 Comorbidities 
 POAD n (%)  7 (8.1) 
 TIA/Stroke, n (%)  4 (4.6) 
 COPD, n (%)  7 (8.1) 
 Atrial fibrillation, n (%) 25 (29.1) 
Table 1: Demographic and clinical characteristics of the study 
population. 
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20.44–25.71%, 3rd tertile: ≥25.72] a trend of increase in EPCs’ 
number at the end of the rehabilitation program was observed 
(data not shown).  
No differences for the cytochemokines, NT-ProBNP and 
hsCRP levels were observed in relation to the improvement in 
exercise capacity (Table 3).  
Significant correlations between EPCs, VEGF and IL-10 
were detected in patients with a median improvement of 
6MWT>23% [CD34+/KDR and IL-10: r=0.42, p=0.007; 
CD133+/KDR+ and IL-10:r=0.41, p=0.009; CD34+/CD133+/ 
KDR+ and IL-10: r=0.40, p=0.01; CD34+/KDR and VEGF: 
r=0.37, p=0.01; CD133+/KDR+ and VEGF: r=0.39, p=0.01 
CD34+/CD133+/KDR+ and VEGF: r=0.39, p=0.01]. In patients 
with a median improvement in 6WTC <23% negative cor-
relations between CRP and EPCs were observed [CD34+/KDR 
and hsCRP: r=- 0.34, p=0.03; CD133+/KDR+ and hsCRP: r= – 
0.35, p=0.02; CD34+/CD133+/KDR+ and hsCRP: r= – 0.40, 
p=0.01 
Discussion 
Cardiac rehabilitation (CR) is indicated for patients undergoing 
cardiac surgery and is associated with a decrease of cardiovascu-
lar morbidity and mortality and a significant improvement of ex-
ercise tolerance and functional capacity. 
In this study we report that after a 15-day rehabilitation peri-
od, even if there is a lack of changes in EPCs’ number in the 
whole group of patients, a higher number of circulating EPCs is 
observed in relation to the improvement of exercise capacity at 
the end of the rehabilitation intervention, as measured by the 
6MWT.  
Furthermore, at the end of the rehabilitation only in patients 
with a better improvement of 6MWT (>23%) significant associ-
ations between EPCs, proangiogenic factors and anti-inflamma-
tory cytokines, were found. 
With their characterization in vascular biology, bone mar-
row-derived EPCs appear to form a natural system for maintain-
ing vascular function, enhancing endothelial repair and neov-
ascularization. After the incorporation into the vasculature, they 
Variable T1 T2 P-value 
CD34+/ KDR+ (cells/μl)    0.27 (0–1.65)   0.26(0–3.92) n.s. 
CD133+/ KDR+ (cells/μl)    0.24 (0–1.18)   0.25(0–1.66) n.s. 
CD34+/CD133+/ KDR+ (cells/μl)    0.16 (0–1.58)   0.16(0–1.43) n.s. 
IL1ra, pg/ml  191.7 (54.5–1910.4) 151.9 (51.9 –1105) <0.0001 
IL-10, pg/ml   35.9 (6.2–122.5)  29.3 (3.4–136.9) <0.0001 
VEGF, pg/ml  166.5 (5.8–858.1) 138.5 (6.8 –776.2) <0.001 
IL-8, pg/ml   23.9 (7.6–231.2)  20.0 (6.9–317) <0.05 
IL-6, pg/ml   28.5 (11.6–100)  18.7 (10.4–152.1) <0.0001 
CRP, mg/L   46 (4.50–187.0)  10 (1.4–75) <0.0001 
NT-ProBNP, pg/ml 1354 (16–12240) 826.9 (103.7–8967) <0.0001 
Values are reported as median and (range). CRP, C-reactive protein; IL-6, interleukin-6; IL-8, interleukin 8; IL-10, interleukin 10; IL1ra, 
interleukin 1 receptor antagonist; NT-ProBNP, N-terminal pro-brain natriuretic peptide; VEGF, vascular endothelial growth factor. 
 
 
 
 
 
 
 
 
 
 
 
 
Variable <23%  ≥23%  P-value 
CD34+/ KDR+ (cells/μl)   0.17 (0–3.92)   0.32 (0–2.71) <0.05 
CD133+/ KDR+ (cells/μl)   0.20 (0–0.87)   0.32 (0–1.66) <0.05 
CD34+/CD133+/ KDR+ (cells/μl)   0.13 (0–0.81)   0.21 (0–1.43) <0.05 
hs-CRP, mg/l  10 (3.2–74)  10 (1.4–75) n.s. 
IL-6, pg/ml  17.9 (10.4–152.1)  19.1 (11.5–33.7) n.s. 
VEGF, pg/ml 174.7 (15.3–730.6) 131.4 (17.5–776.2) n.s. 
IL-8, pg/ml  20.2 (6.9–80.8)  19.7 (8–317.0) n.s. 
IL-10, pg/ml  32.7 (5.4–98.3)  28.0 (3.4–136.9) n.s. 
IL-1ra, pg/ml 183.5 (77.5–1105.0) 147.5 (59.8–898.8) <0.05 
NT-ProBNP, pg/ml 711 (248.9–5439.0) 811.0 (126.4–8967.0) n.s. 
Values are reported as median and (range), CRP, C-reactive protein; IL-6, interleukin-6; IL-8, interleukin 8; IL-10, interleukin 10; IL1ra, 
interleukin 1 receptor antagonist; NT-ProBNP, N-terminal pro-brain natriuretic peptide; VEGF, vascular endothelial growth factor. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Modifications of cytokines, NT-
ProBNP and C-reactive protein between 
T1 and T2. 
Table 3: Differences in EPC number, cy-
tochemokines, hs-CRP and NT-ProBNP 
according to the median improvement in 
6MWT at T2. 
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are able to differentiate into mature endothelial cells and to re-
lease angiogenic growth factors such as VEGF and stromal de-
rived factor-1, which act in a paracrine manner to support local 
angiogenesis and mobilise tissue residing progenitor cells (20).  
At present, different methods have been carried out to deter-
mine EPCs (flow cytometry or in-vitro cell culture assays) and 
there is a considerable debate on which set of markers is suffi-
cient to identify these types of cells. The use of markers as CD34, 
CD133 and KDR for EPCs’ identification is one of the most 
widely used system that allow to analyse at the same time three 
(CD34+/KDR+; CD133+/KDR+; CD34+/CD133+/KDR+) 
possible EPCs’ populations. 
The effects of physical exercise on EPCs’ levels and function 
has been previously described in both patients with vascular dis-
ease and healthy subjects, showing an increase of circulating 
EPCs (4–7). This may represent an important beneficial out-
come of physical exercise, probably mediated by a shear stress-
induced upregulation of endothelial nitric oxide synthase (8). 
However, only one study is available on patients who underwent 
a CR intervention after cardiac surgery and/or PCI: Paul et al. 
(13) recently showed that, after an exercise protocol lasting for 
three months, an increase of circulating EPCs’ number, survival 
and differentiation in coronary artery disease patients after PCI 
or coronary artery bypass grafting, takes place. Our study reports 
the effect of a shorter period of rehabilitation program, extending 
findings on cytochemokines’ profile and on the improvement of 
exercise capacity. The lack of a significant EPCs’ increase at the 
end of the rehabilitation program observed in the whole patients 
group can be due to several different mechanisms. From one 
side, the duration of CR protocol could be insufficient to deter-
mine a significant mobilization of EPCs from the bone marrow 
to peripheral circulation. 
On the other side, our study population comprised only pa-
tients that have previously experienced a cardiac surgery (CABG 
or valve replacement) and it’s possible that the surgical interven-
tion, through the release of pro-inflammatory cytokines, deter-
mined a different baseline value of EPCs with respect to the pa-
tients of Paul et al. In addition, patients described by Paul et al., 
were on optimal statin therapy for al least one month, and it has 
been previously demonstrated that lipid-lowering therapy can 
determine an increase of EPCs in the circulation.  
Actually, a various number of mediators has been reported to 
mobilise EPCs from the bone marrow, and in particular an im-
portant role seems to be ascribed to the angiogenic cytokines 
VEGF that is demonstrated to be able to mobilise circulating 
progenitor cells in animal models (21) and in patients with acute 
myocardial infarction (22). We have recently demonstrated a 
positive association between EPCs numbers and IL-10 levels and 
in this study we confirm our previous findings (14).  
The precise mechanisms involved in this relation remained to 
be defined, but the inflammatory balance might play a relevant 
role in the modulation of EPCs’ mobilisation. We can speculate 
that the anti-inflammatory cytokine IL-10 is able to modulate 
EPCs’ mobilization probably through the inhibition of the CRP, 
which is known to cause a significant reduction of EPCs’ differ-
entiation, survival and function (23). In fact, in our patients with 
a modest improvement of the 6MWT<23%, a negative cor-
relation between EPCs and hsCRP has been reported. 
Moreover, at baseline, in the whole study population a sig-
nificant association between EPCs and IL-8 has been observed. 
IL-8 is a cytochemokine that exerts pro-angiogenic effects, and 
various studies showed that is able to induce stem cell mobili-
sation through the activation of matrix metalloproteinases and 
the degradation of extracellular matrix in the stem cells niche 
(12).  
At the end of the rehabilitation program a significant de-
crease of pro and anti-inflammatory cytokines, CRP and NT-
ProBNP was observed, without any substantial difference in cy-
tochemokines profile between patients with a median improve-
ment of 6MWT≥23% with respect to patients with a median im-
provement <23%. 
For this reason, the differences in EPCs’ number that we ob-
served between the two groups cannot be ascribed to a different 
pattern of cytochemokines at the end of rehabilitation. There-
fore, it’s rather possible to hypothesise that, despite of similar 
levels of circulating cytochemokines, a different bone marrow 
response to the stimulus is a determinant for the differences be-
tween the two groups of patients.  
Despite no significant differences in the levels of pro-inflam-
matory cytokines between the two groups, the difference de-
tected for the IL1ra levels can reflect an up-regulation of this cy-
tokine due to a more pronounced inflammatory state present in 
the group without an important improvement of the 6MWT. 
A possible limitation of this study is the observational design 
that does not allow us to determine if the different number of 
EPCs in the two groups of patients after the rehabilitation inter-
vention is a cause or effect of the better improvement in exercise 
capacity; however, this is the first study that reported EPCs’ 
number in relation to the improvement of exercise capacity and 
cytochemokines in this type of clinical setting. Another limi-
tation can be identified in the use of the 6MWT that is a simple 
functional test possibly influenced by several parameters. How-
ever, 6MWT is a widely-used tool, reliable to assess physical 
What is known about this topic ? 
− Endothelial progenitor cells (EPCs) contribute to en-
dothelial regeneration and postnatal neovascularization.  
− Physical exercise is able to mobilize EPCs from the bone 
marrow. 
− Only one study reported an increase of circulating EPCs 
after a three-month cardiac rehabilitation program. 
What does this paper add? 
− Even after a short (15-days) rehabilitation period, a 
higher number of circulating EPCs is observed in relation 
to the improvement of exercise capacity as measured by 
the six-minute walk test. 
− After a cardiac rehabilitation period a significant de-
crease of cytochemokines, C-reactive protein and NT-
ProBNP was oserved. 
− The association between VEGF, IL-10 and IL-8 with 
EPCs’ number, suggests their role in favouring the mo-
bilisation of these particular type of progenitor cells. 
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performance, even in patients who are not able to perform stan-
dard maximal symptom-limited exercise tests, such as elderly 
and severely limited patients. 
In conclusion, in this study we observed that the improve-
ment of exercise capacity after a short period of rehabilitation in-
tervention is associated to modifications of EPCs’ number in pa-
tients who underwent cardiac surgery. Furthermore, a decrease 
of cytochemokines, CRP and NT-ProBNP and an improvement 
of exercise capacity was detected. However we were not able to 
demonstrate if the decrease of cytochemokines and neuro-humo-
ral factors was related to a beneficial effect of cardiac rehabili-
tation “per se” or represents only the effect of the natural course 
of the postoperative period. 
In addition, the association between VEGF, IL-10 and IL-8 
with EPCs’ number, both at baseline and in the patients group 
with an improvement in 6MWT≥23%, suggests a role in favour-
ing the mobilisation of these particular type of progenitor cells.  
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